Risk of infections in patients with psoriasis treated with biologic agents and new oral small molecules. BIOBADADERM Registry - PubMed
3 hours ago
- #psoriasis
- #biologics
- #infection-risk
- Infections are the most common adverse events in psoriasis systemic treatment.
- Study analyzed infection risks using BIOBADADERM registry data (4,820 patients, 8,826 treatment cycles, 20,829 patient-years).
- Overall serious infection incidence was low (5.33%), highest with infliximab.
- Most frequent serious infections: pneumonia, COVID-19 pneumonia, cellulitis.
- Non-serious infections: respiratory tract infections, COVID-19, urinary tract infections most common.
- Risankizumab and ustekinumab showed significantly lower overall infection risk vs. adalimumab.
- Higher Candida infection risk with bimekizumab, brodalumab, secukinumab, ixekizumab.
- Guselkumab, secukinumab, ixekizumab, ustekinumab linked to reduced respiratory infections.
- Ixekizumab associated with lower COVID-19 risk; dimethyl fumarate showed increased risk.
- Findings support favorable safety profile of biologics/small molecules for psoriasis.